{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:24:49Z","timestamp":1787063089742,"version":"build-2736575974"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10787-025-01963-z","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:25:20Z","timestamp":1759134320000},"page":"5835-5859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted biologic therapies and advanced drug delivery approaches in asthma management: a clinical perspective"],"prefix":"10.1007","volume":"33","author":[{"given":"Nousheen","family":"Khatoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjila","family":"Firdous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Hirwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushmaan","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Adnan","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-9509","authenticated-orcid":false,"family":"Ajazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"1963_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2015.11.002","volume":"111","author":"R Aalbers","year":"2016","unstructured":"Aalbers R, Vogelmeier C, Kuna P (2016) Achieving asthma control with ICS\/LABA: a review of strategies for asthma management and prevention. Respir Med 111:1\u20137. https:\/\/doi.org\/10.1016\/j.rmed.2015.11.002","journal-title":"Respir Med"},{"key":"1963_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1556-276X-9-247","volume":"9","author":"E Abbasi","year":"2014","unstructured":"Abbasi E, Aval SF, Akbarzadeh A et al (2014) Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett 9:1\u201310. https:\/\/doi.org\/10.1186\/1556-276X-9-247","journal-title":"Nanoscale Res Lett"},{"key":"1963_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.14202\/vetworld.2018.627-635","volume":"11","author":"LA Abdulkhaleq","year":"2018","unstructured":"Abdulkhaleq LA, Assi MA, Abdullah R et al (2018) The crucial roles of inflammatory mediators in inflammation: a review. Vet World 11:627\u2013635. https:\/\/doi.org\/10.14202\/vetworld.2018.627-635","journal-title":"Vet World"},{"key":"1963_CR4","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.5c00498","author":"M Adnan Raza","year":"2025","unstructured":"Adnan Raza M, Firdous A, Gupta U et al (2025) Emerging trends in designing the dendrimer-based drug delivery for antineoplastic therapies. ACS Appl Bio Mater. https:\/\/doi.org\/10.1021\/acsabm.5c00498","journal-title":"ACS Appl Bio Mater"},{"issue":"1","key":"1963_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s43141-023-00577-8","volume":"21","author":"PA Akinnusi","year":"2023","unstructured":"Akinnusi PA, Olubode SO, Adebesin AO et al (2023) Optimal molecular binding data and pharmacokinetic profiles of novel potential triple-action inhibitors of chymase, spleen tyrosine kinase, and prostaglandin D2 receptor in the treatment of asthma. J Genet Eng Biotechnol 21(1):113. https:\/\/doi.org\/10.1186\/s43141-023-00577-8","journal-title":"J Genet Eng Biotechnol"},{"key":"1963_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hsr.2023.100103","volume":"8","author":"N Alam","year":"2023","unstructured":"Alam N, Latha S, Kumar A (2023) Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: a systematic review and meta-analysis of randomized controlled trials. Heal Sci Rev 8:100103. https:\/\/doi.org\/10.1016\/j.hsr.2023.100103","journal-title":"Heal Sci Rev"},{"key":"1963_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/jpm12050673","volume":"12","author":"MA Alghamdi","year":"2022","unstructured":"Alghamdi MA, Fallica AN, Virz\u00ec N et al (2022) The promise of nanotechnology in personalized medicine. J Pers Med 12:673. https:\/\/doi.org\/10.3390\/jpm12050673","journal-title":"J Pers Med"},{"key":"1963_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12090793","author":"SA Alqarni","year":"2022","unstructured":"Alqarni SA, Bineid A, Ahmad SF et al (2022) Blockade of tyrosine kinase, LCK leads to reduction in airway inflammation through regulation of pulmonary Th2\/Treg balance and oxidative stress in cockroach extract-induced mouse model of allergic asthma. Metabolites. https:\/\/doi.org\/10.3390\/metabo12090793","journal-title":"Metabolites"},{"key":"1963_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2023.100129","volume":"11","author":"M Amin","year":"2023","unstructured":"Amin M, Hadi M, Jafari E (2023) Opennano niosome nanocarrier enhances the ameliorating effects of myrtenol in the lungs of rats with experimental asthma. Open Nano 11:100129. https:\/\/doi.org\/10.1016\/j.onano.2023.100129","journal-title":"Open Nano"},{"key":"1963_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jconrel.2022.03.028","volume":"346","author":"S Arber","year":"2022","unstructured":"Arber S, Alyan M, Egorov E et al (2022) Lung targeted liposomes for treating ARDS. J Control Release 346:421\u2013433","journal-title":"J Control Release"},{"key":"1963_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017017845","volume":"34","author":"UA Ashfaq","year":"2017","unstructured":"Ashfaq UA, Riaz M, Yasmeen E, Yousaf M (2017) Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment. Crit Rev Ther Drug Carrier Syst 34:317\u2013353. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2017017845","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"1963_CR12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/toxics11120974","volume":"11","author":"B Bakan","year":"2023","unstructured":"Bakan B, Jonckheere A, Decaesteker T et al (2023) Impact of a polymer-based nanoparticle with formoterol drug as nanocarrier system in vitro and in an experimental asthmatic model. Toxic 11:974","journal-title":"Toxic"},{"key":"1963_CR13","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.3109\/10717544.2016.1170247","volume":"23","author":"JS Barbosa","year":"2016","unstructured":"Barbosa JS, Almeida Paz FA, Braga SS (2016) Montelukast medicines of today and tomorrow: from molecular pharmaceutics to technological formulations. Drug Deliv 23:3257\u20133265. https:\/\/doi.org\/10.3109\/10717544.2016.1170247","journal-title":"Drug Deliv"},{"key":"1963_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2023.E18710","volume":"9","author":"T Bashkeran","year":"2023","unstructured":"Bashkeran T, Kamaruddin AH, Ngo TX et al (2023) Niosomes in cancer treatment: a focus on curcumin encapsulation. Heliyon 9:e18710. https:\/\/doi.org\/10.1016\/J.HELIYON.2023.E18710","journal-title":"Heliyon"},{"key":"1963_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3947\/ic.2020.0109","volume":"53","author":"K Bhatt","year":"2021","unstructured":"Bhatt K, Garimella R, Taugir R et al (2021) Effectiveness of mavrilimumab in viral infections including SARS-CoV-2 infection\u2014a brief review. Infect Chemother 53:1. https:\/\/doi.org\/10.3947\/ic.2020.0109","journal-title":"Infect Chemother"},{"key":"1963_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101336","volume":"54","author":"S Bonde","year":"2019","unstructured":"Bonde S, Tambe K (2019) Lectin coupled liposomes for pulmonary delivery of salbutamol sulphate for better management of asthma: formulation development using qbd approach. J Drug Deliv Sci Technol 54:101336. https:\/\/doi.org\/10.1016\/j.jddst.2019.101336","journal-title":"J Drug Deliv Sci Technol"},{"key":"1963_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2023.123756","volume":"394","author":"B Budav\u00e1ri","year":"2024","unstructured":"Budav\u00e1ri B, Karancsi \u00c1, Pinke BG et al (2024) Long-term shelf-life liposomes for delivery of prednisolone and budesonide. J Mol Liq 394:123756. https:\/\/doi.org\/10.1016\/j.molliq.2023.123756","journal-title":"J Mol Liq"},{"key":"1963_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101128","volume":"53","author":"MD Buhecha","year":"2019","unstructured":"Buhecha MD, Lansley AB, Somavarapu S, Pannala AS (2019) Development and characterization of PLA nanoparticles for pulmonary drug delivery: co-encapsulation of theophylline and budesonide, a hydrophilic and lipophilic drug. J Drug Deliv Sci Technol 53:101128. https:\/\/doi.org\/10.1016\/j.jddst.2019.101128","journal-title":"J Drug Deliv Sci Technol"},{"key":"1963_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/17425247.2023.2185220","volume":"20","author":"SP Carneiro","year":"2023","unstructured":"Carneiro SP, Greco A, Chiesa E et al (2023) Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases. Expert Opin Drug Deliv 20:471\u2013487. https:\/\/doi.org\/10.1080\/17425247.2023.2185220","journal-title":"Expert Opin Drug Deliv"},{"key":"1963_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40291-021-00514-w","volume":"25","author":"M Cazzola","year":"2021","unstructured":"Cazzola M, Ora J, Cavalli F et al (2021) Treatable mechanisms in asthma. Mol Diagn Ther 25:111\u2013121. https:\/\/doi.org\/10.1007\/s40291-021-00514-w","journal-title":"Mol Diagn Ther"},{"key":"1963_CR21","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1111\/all.14607","volume":"75","author":"L Cevhertas","year":"2020","unstructured":"Cevhertas L, Ogulur I, Maurer DJ et al (2020) Advances and recent developments in asthma in 2020. Allergy 75:3124\u20133146. https:\/\/doi.org\/10.1111\/all.14607","journal-title":"Allergy"},{"key":"1963_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1183\/16000617.0069-2015","volume":"25","author":"J Charriot","year":"2016","unstructured":"Charriot J, Vachier I, Halimi L et al (2016) Future treatment for asthma. Eur Respir Rev 25:77\u201392. https:\/\/doi.org\/10.1183\/16000617.0069-2015","journal-title":"Eur Respir Rev"},{"key":"1963_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111903","volume":"132","author":"Y Choi","year":"2024","unstructured":"Choi Y, Kim S-H, Jun Shin S et al (2024) The effect of Bruton\u2019s tyrosine kinase (BTK) inhibitor in the eosinophilic asthma model of mouse. Int Immunopharmacol 132:111903. https:\/\/doi.org\/10.1016\/j.intimp.2024.111903","journal-title":"Int Immunopharmacol"},{"key":"1963_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.tips.2020.08.002","volume":"41","author":"MYT Chow","year":"2020","unstructured":"Chow MYT, Qiu Y, Lam JKW (2020) Inhaled RNA therapy: from promise to reality. Trends Pharmacol Sci 41:715\u2013729. https:\/\/doi.org\/10.1016\/j.tips.2020.08.002","journal-title":"Trends Pharmacol Sci"},{"key":"1963_CR25","doi-asserted-by":"publisher","DOI":"10.14218\/JERP.2022.00086","author":"MP Chudasma","year":"2023","unstructured":"Chudasma MP, Shah SA, Qureshi MHN et al (2023) Brief insight on nanovesicular liposomes as drug-delivery carriers for medical applications. J Explor Res Pharmacol. https:\/\/doi.org\/10.14218\/JERP.2022.00086","journal-title":"J Explor Res Pharmacol"},{"key":"1963_CR26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/ph17081059","volume":"17","author":"E Cojocaru","year":"2024","unstructured":"Cojocaru E, Petri\u0219 OR, Cojocaru C (2024) Nanoparticle-based drug delivery systems in inhaled therapy: improving respiratory medicine. Pharmaceuticals 17:1059. https:\/\/doi.org\/10.3390\/ph17081059","journal-title":"Pharmaceuticals"},{"key":"1963_CR27","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1021\/acs.biomac.2c00576","volume":"23","author":"EF Craparo","year":"2022","unstructured":"Craparo EF, Cabibbo M, Scialabba C et al (2022) Inhalable formulation based on lipid-polymer hybrid nanoparticles for the macrophage targeted delivery of Roflumilast. Biomacromol 23:3439\u20133451. https:\/\/doi.org\/10.1021\/acs.biomac.2c00576","journal-title":"Biomacromol"},{"key":"1963_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.rmed.2005.11.020","volume":"100","author":"R Dahl","year":"2006","unstructured":"Dahl R (2006) Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 100:1307\u20131317. https:\/\/doi.org\/10.1016\/j.rmed.2005.11.020","journal-title":"Respir Med"},{"key":"1963_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123841","volume":"653","author":"YH Dallal Bashi","year":"2024","unstructured":"Dallal Bashi YH, Ali A, Al Ayoub Y et al (2024) Inhaled dry powder liposomal azithromycin for treatment of chronic lower respiratory tract infection. Int J Pharm 653:123841. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.123841","journal-title":"Int J Pharm"},{"key":"1963_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11100521","volume":"11","author":"MG Dogbe","year":"2019","unstructured":"Dogbe MG, Mafilaza AY, Eleut\u00e9rio CV et al (2019) Pharmaceutical benefits of fluticasone propionate association to delivery systems. In vitro and in vivo evaluation. Pharmaceutics 11:521. https:\/\/doi.org\/10.3390\/pharmaceutics11100521","journal-title":"Pharmaceutics"},{"key":"1963_CR31","unstructured":"Economics P, Khaldoon A, Ahmad A et al (2020) No \u4e3b\u89b3\u7684\u5065\u5eb7\u611f\u3092\u4e2d\u5fc3\u3068\u3057\u305f\u5728\u5b85\u9ad8\u9f62\u8005\u306b\u304a\u3051\u308b \u5065\u5eb7\u95a2\u9023\u6307\u6a19\u306b\u95a2\u3059\u308b\u5171\u5206\u6563\u69cb\u9020\u5206\u6790Title"},{"key":"1963_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ijpharm.2006.04.023","volume":"319","author":"M Elsamaligy","year":"2006","unstructured":"Elsamaligy M, Afifi N, Mahmoud E (2006) Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int J Pharm 319:121\u2013129. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.04.023","journal-title":"Int J Pharm"},{"key":"1963_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1525-0016(03)00003-0","volume":"7","author":"P Factor","year":"2003","unstructured":"Factor P (2003) Gene therapy for asthma. Mol Ther 7:148\u2013152. https:\/\/doi.org\/10.1016\/S1525-0016(03)00003-0","journal-title":"Mol Ther"},{"key":"1963_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV (2015) Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol 15:57\u201365. https:\/\/doi.org\/10.1038\/nri3786","journal-title":"Nat Rev Immunol"},{"key":"1963_CR35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/pharmaceutics14061193","volume":"14","author":"Y Fan","year":"2022","unstructured":"Fan Y, Yang Z (2022) Inhaled siRNA formulations for respiratory diseases: from basic research to clinical application. Pharmaceutics 14:1193. https:\/\/doi.org\/10.3390\/pharmaceutics14061193","journal-title":"Pharmaceutics"},{"key":"1963_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3","author":"HA Farne","year":"2017","unstructured":"Farne HA, Wilson A, Powell C et al (2017) Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010834.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1963_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm.2755","volume":"18","author":"SJ Galli","year":"2012","unstructured":"Galli SJ, Tsai M (2012) IgE and mast cells in allergic disease. Nat Med 18:693\u2013704. https:\/\/doi.org\/10.1038\/nm.2755","journal-title":"Nat Med"},{"key":"1963_CR38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jaci.2021.08.013","volume":"148","author":"SN Georas","year":"2021","unstructured":"Georas SN, Donohue P, Connolly M, Wechsler ME (2021) JAK inhibitors for asthma. J Allergy Clin Immunol 148:953\u2013963. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.013","journal-title":"J Allergy Clin Immunol"},{"key":"1963_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.839011","volume":"13","author":"Y Gon","year":"2022","unstructured":"Gon Y, Maruoka S, Mizumura K (2022) Omalizumab and IgE in the control of severe allergic asthma. Front Pharmacol 13:1\u20138. https:\/\/doi.org\/10.3389\/fphar.2022.839011","journal-title":"Front Pharmacol"},{"key":"1963_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/1744666X.2017.1241711","volume":"13","author":"MA Goodman","year":"2017","unstructured":"Goodman MA, Moradi Manesh D, Malik P, Rothenberg ME (2017) CRISPR\/Cas9 in allergic and immunologic diseases. Expert Rev Clin Immunol 13:5\u20139. https:\/\/doi.org\/10.1080\/1744666X.2017.1241711","journal-title":"Expert Rev Clin Immunol"},{"key":"1963_CR41","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","volume":"184","author":"H Hammad","year":"2021","unstructured":"Hammad H, Lambrecht BN (2021) The basic immunology of asthma. Cell 184:1469\u20131485. https:\/\/doi.org\/10.1016\/j.cell.2021.02.016","journal-title":"Cell"},{"key":"1963_CR42","doi-asserted-by":"crossref","unstructured":"Holgate ST, Thomas M (2017) Asthma. In: Middleton\u2019s allergy essentials. Elsevier, pp 151\u2013204","DOI":"10.1016\/B978-0-323-37579-5.00007-6"},{"key":"1963_CR43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2147\/DDDT.S39100","volume":"8","author":"KLE Hon","year":"2014","unstructured":"Hon KLE, Leung TF, Leung AKC (2014) Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug des Devel Ther 8:839\u2013850. https:\/\/doi.org\/10.2147\/DDDT.S39100","journal-title":"Drug des Devel Ther"},{"key":"1963_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.iac.2022.04.008","volume":"42","author":"A Hudler","year":"2022","unstructured":"Hudler A, Holguin F (2022) Pathophysiology of asthma\u2014chronic obstructive pulmonary disease overlap. Immunol Allergy Clin 42:521\u2013532. https:\/\/doi.org\/10.1016\/j.iac.2022.04.008","journal-title":"Immunol Allergy Clin"},{"key":"1963_CR45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.iac.2022.04.008","volume":"42","author":"A Hudler","year":"2022","unstructured":"Hudler A, Holguin F, Sharma S (2022) Pathophysiology of asthma-chronic obstructive pulmonary disease overlap. Immunol Allergy Clin North Am 42:521\u2013532. https:\/\/doi.org\/10.1016\/j.iac.2022.04.008","journal-title":"Immunol Allergy Clin North Am"},{"key":"1963_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12964-024-01713-8","volume":"22","author":"BM Hussen","year":"2024","unstructured":"Hussen BM, Najmadden ZB, Abdullah SR et al (2024) CRISPR\/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders. Cell Commun Signal 22:329. https:\/\/doi.org\/10.1186\/s12964-024-01713-8","journal-title":"Cell Commun Signal"},{"key":"1963_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/17425247.2023.2175814","volume":"20","author":"T Hye","year":"2023","unstructured":"Hye T, Moinuddin SM, Sarkar T et al (2023) An evolving perspective on novel modified release drug delivery systems for inhalational therapy. Expert Opin Drug Deliv 20:335\u2013348. https:\/\/doi.org\/10.1080\/17425247.2023.2175814","journal-title":"Expert Opin Drug Deliv"},{"key":"1963_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPB.2024.114242","volume":"198","author":"DC J\u00fcrgens","year":"2024","unstructured":"J\u00fcrgens DC, M\u00fcller JT, Nguyen A, Merkel OM (2024) Tailoring lipid nanoparticles for T-cell targeting in allergic asthma: insights into efficacy and specificity. Eur J Pharm Biopharm 198:114242. https:\/\/doi.org\/10.1016\/J.EJPB.2024.114242","journal-title":"Eur J Pharm Biopharm"},{"key":"1963_CR49","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jconrel.2023.01.014","volume":"354","author":"R Kandil","year":"2023","unstructured":"Kandil R, Baldassi D, B\u00f6hlen S et al (2023) Targeted GATA3 knockdown in activated T cells via pulmonary siRNA delivery as novel therapy for allergic asthma. J Control Release 354:305\u2013315. https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.014","journal-title":"J Control Release"},{"key":"1963_CR50","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/joim.12280","volume":"276","author":"RM Kannan","year":"2014","unstructured":"Kannan RM, Nance E, Kannan S, Tomalia DA (2014) Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications. J Intern Med 276:579\u2013617. https:\/\/doi.org\/10.1111\/joim.12280","journal-title":"J Intern Med"},{"key":"1963_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.983852","author":"G Kardas","year":"2022","unstructured":"Kardas G, Panek M, Kuna P et al (2022) Monoclonal antibodies in the management of asthma: dead ends, current status and future perspectives. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.983852","journal-title":"Front Immunol"},{"key":"1963_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.518345","author":"T Kawamatawong","year":"2021","unstructured":"Kawamatawong T (2021) Phosphodiesterase-4 inhibitors for non-COPD respiratory diseases. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.518345","journal-title":"Front Pharmacol"},{"key":"1963_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1634","author":"TWM Keil","year":"2020","unstructured":"Keil TWM, Baldassi D, Merkel OM (2020) T-cell targeted pulmonary siRNA delivery for the treatment of asthma. Wires Nanomed Nanobiotechnol. https:\/\/doi.org\/10.1002\/wnan.1634","journal-title":"Wires Nanomed Nanobiotechnol"},{"key":"1963_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/B978-008055232-3.62454-7","author":"KK Kiningham","year":"2007","unstructured":"Kiningham KK (2007) Prednisolone. xPharm Compr Pharmacol Ref. https:\/\/doi.org\/10.1016\/B978-008055232-3.62454-7","journal-title":"xPharm Compr Pharmacol Ref"},{"key":"1963_CR55","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.3390\/molecules29225293","volume":"29","author":"B Krav\u010denia","year":"2024","unstructured":"Krav\u010denia B, Ma\u015blanka T (2024) Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, and tofacitinib, a janus kinase inhibitor, attenuate airway inflammation and hyperresponsiveness in a mouse model of allergic asthma. Molecules 29:5293. https:\/\/doi.org\/10.3390\/molecules29225293","journal-title":"Molecules"},{"key":"1963_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/102418","volume":"2013","author":"F Lavorini","year":"2013","unstructured":"Lavorini F (2013) The challenge of delivering therapeutic aerosols to asthma patients. ISRN Allergy 2013:1\u201317. https:\/\/doi.org\/10.1155\/2013\/102418","journal-title":"ISRN Allergy"},{"key":"1963_CR57","doi-asserted-by":"publisher","first-page":"9985","DOI":"10.3390\/cimb45120624","volume":"45","author":"BS Lukhele","year":"2023","unstructured":"Lukhele BS, Bassey K, Witika BA (2023) The utilization of plant-material-loaded vesicular drug delivery systems in the management of pulmonary diseases. Curr Issues Mol Biol 45:9985\u201310017. https:\/\/doi.org\/10.3390\/cimb45120624","journal-title":"Curr Issues Mol Biol"},{"key":"1963_CR58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3892\/mmr.2021.11964","volume":"23","author":"M-X Luo","year":"2021","unstructured":"Luo M-X, Hua S, Shang Q-Y (2021) Application of nanotechnology in drug delivery systems for respiratory diseases (review). Mol Med Rep 23:325. https:\/\/doi.org\/10.3892\/mmr.2021.11964","journal-title":"Mol Med Rep"},{"key":"1963_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104473","volume":"84","author":"GA Mariya","year":"2023","unstructured":"Mariya GA, Ramar M, Henry LJK et al (2023) Fabrication of chitosan-based redox-responsive polymeric nanoparticles: In-vitro and in-vivo evaluation for treating airway inflammation in asthma. J Drug Deliv Sci Technol 84:104473. https:\/\/doi.org\/10.1016\/j.jddst.2023.104473","journal-title":"J Drug Deliv Sci Technol"},{"key":"1963_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms232214207","volume":"23","author":"L Marques","year":"2022","unstructured":"Marques L, Vale N (2022) Salbutamol in the management of asthma: a review. Int J Mol Sci 23:1\u201319. https:\/\/doi.org\/10.3390\/ijms232214207","journal-title":"Int J Mol Sci"},{"key":"1963_CR61","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1753465817717134","volume":"11","author":"J M\u00e1spero","year":"2017","unstructured":"M\u00e1spero J (2017) Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects. Ther Adv Respir Dis 11:311\u2013325. https:\/\/doi.org\/10.1177\/1753465817717134","journal-title":"Ther Adv Respir Dis"},{"key":"1963_CR62","doi-asserted-by":"crossref","unstructured":"McClean N, Hasday JD, Shapiro P (2023) Progress in the development of kinase inhibitors for treating asthma and COPD. pp 145\u2013178","DOI":"10.1016\/bs.apha.2023.04.004"},{"key":"1963_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/biom14020195","volume":"14","author":"AS Melani","year":"2024","unstructured":"Melani AS, Croce S, Fabbri G et al (2024) Inhaled corticosteroids in subjects with chronic obstructive pulmonary disease: an old, unfinished history. Biomolecules 14:195. https:\/\/doi.org\/10.3390\/biom14020195","journal-title":"Biomolecules"},{"key":"1963_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/BTT.S326422","volume":"15","author":"MA Mengstie","year":"2021","unstructured":"Mengstie MA, Wondimu BZ (2021) Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biol Targets Ther 15:353\u2013361. https:\/\/doi.org\/10.2147\/BTT.S326422","journal-title":"Biol Targets Ther"},{"key":"1963_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23092205","author":"Z Mhlwatika","year":"2018","unstructured":"Mhlwatika Z, Aderibigbe BA (2018) Application of dendrimers for the treatment of infectious diseases. Molecules. https:\/\/doi.org\/10.3390\/molecules23092205","journal-title":"Molecules"},{"key":"1963_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09241-6","volume":"12","author":"J Milara","year":"2022","unstructured":"Milara J, Ballester B, de Diego A et al (2022) The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro. Sci Rep 12:5132. https:\/\/doi.org\/10.1038\/s41598-022-09241-6","journal-title":"Sci Rep"},{"key":"1963_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2025.117412","author":"EN Morales","year":"2025","unstructured":"Morales EN, Malecki CC, Maruri A et al (2025) Preclinical evaluation of N-acetyl-cysteine in association with liposomes of lung surfactant\u2019s lipids for the treatment of pulmonary fibrosis and asthma. Toxicol Appl Pharmacol. https:\/\/doi.org\/10.1016\/j.taap.2025.117412","journal-title":"Toxicol Appl Pharmacol"},{"key":"1963_CR68","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03179-2021","volume":"60","author":"K Mortimer","year":"2022","unstructured":"Mortimer K, Reddel HK, Pitrez PM, Bateman ED (2022) Asthma management in low and middle income countries: case for change. Eur Respir J 60:2103179. https:\/\/doi.org\/10.1183\/13993003.03179-2021","journal-title":"Eur Respir J"},{"key":"1963_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104441","volume":"148","author":"A Nadeem","year":"2019","unstructured":"Nadeem A, Ahmad SF, Al-harbi NO et al (2019) Inhibition of Bruton\u2019 s tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway in fl ammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy. Pharmacol Res 148:104441. https:\/\/doi.org\/10.1016\/j.phrs.2019.104441","journal-title":"Pharmacol Res"},{"key":"1963_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109920","volume":"117","author":"A Nadeem","year":"2023","unstructured":"Nadeem A, Alshehri S, Al-Harbi NO et al (2023) Bruton\u2019s tyrosine kinase inhibition suppresses neutrophilic inflammation and restores histone deacetylase 2 expression in myeloid and structural cells in a mixed granulocytic mouse model of asthma. Int Immunopharmacol 117:109920. https:\/\/doi.org\/10.1016\/j.intimp.2023.109920","journal-title":"Int Immunopharmacol"},{"key":"1963_CR71","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jconrel.2023.12.012","volume":"366","author":"MT Neary","year":"2024","unstructured":"Neary MT, Mulder LM, Kowalski PS et al (2024) Nebulised delivery of RNA formulations to the lungs: from aerosol to cytosol. J Control Release 366:812\u2013833. https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.012","journal-title":"J Control Release"},{"key":"1963_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.colsurfb.2018.08.027","volume":"172","author":"ZY Ng","year":"2018","unstructured":"Ng ZY, Wong J-Y, Panneerselvam J et al (2018) Assessing the potential of liposomes loaded with curcumin as a therapeutic intervention in asthma. Colloids Surf B Biointerfaces 172:51\u201359. https:\/\/doi.org\/10.1016\/j.colsurfb.2018.08.027","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1963_CR73","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.2147\/DDDT.S354291","volume":"16","author":"M Nilsson","year":"2022","unstructured":"Nilsson M, Rhedin M, Hendrickx R et al (2022) Characterization of selective and potent JAK1 inhibitors intended for the inhaled treatment of Asthma. Drug des Devel Ther 16:2901\u20132917. https:\/\/doi.org\/10.2147\/DDDT.S354291","journal-title":"Drug des Devel Ther"},{"key":"1963_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011801.pub2","author":"R Normansell","year":"2016","unstructured":"Normansell R, Kew KM, Mansour G (2016) Different oral corticosteroid regimens for acute asthma. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011801.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1963_CR75","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.alit.2020.01.004","volume":"69","author":"Y Okayama","year":"2020","unstructured":"Okayama Y, Matsumoto H, Odajima H et al (2020) Roles of omalizumab in various allergic diseases. Allergol Int 69:167\u2013177. https:\/\/doi.org\/10.1016\/j.alit.2020.01.004","journal-title":"Allergol Int"},{"key":"1963_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/dj11050113","volume":"11","author":"EM Pacheco-Quito","year":"2023","unstructured":"Pacheco-Quito EM, Jaramillo J, Sarmiento-Ordo\u00f1ez J, Cuenca-Le\u00f3n K (2023) Drugs prescribed for asthma and their adverse effects on dental health. Dent J 11:1\u201323. https:\/\/doi.org\/10.3390\/dj11050113","journal-title":"Dent J"},{"key":"1963_CR77","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/JAA.S342391","volume":"17","author":"R Panettieri Jr","year":"2024","unstructured":"Panettieri R Jr, Lugogo N, Corren J, Ambrose C (2024) Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy 17:219\u2013236. https:\/\/doi.org\/10.2147\/JAA.S342391","journal-title":"J Asthma Allergy"},{"key":"1963_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-020-00472-8","volume":"16","author":"A Papi","year":"2020","unstructured":"Papi A, Blasi F, Canonica GW et al (2020) Treatment strategies for asthma: reshaping the concept of asthma management. Allergy, Asthma Clin Immunol 16:1\u201311. https:\/\/doi.org\/10.1186\/s13223-020-00472-8","journal-title":"Allergy, Asthma Clin Immunol"},{"key":"1963_CR79","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/14712598.2018.1492540","volume":"18","author":"SS Patel","year":"2018","unstructured":"Patel SS, Casale TB, Cardet JC (2018) Biological therapies for eosinophilic asthma. Expert Opin Biol Ther 18:747\u2013754. https:\/\/doi.org\/10.1080\/14712598.2018.1492540","journal-title":"Expert Opin Biol Ther"},{"key":"1963_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF et al (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 16:1\u201333. https:\/\/doi.org\/10.1186\/s12951-018-0392-8","journal-title":"J Nanobiotechnology"},{"key":"1963_CR81","doi-asserted-by":"publisher","first-page":"46830","DOI":"10.1007\/s11356-022-19158-2","volume":"29","author":"KR Paudel","year":"2022","unstructured":"Paudel KR, Mehta M, Yin GHS et al (2022) Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro. Environ Sci Pollut Res 29:46830\u201346847. https:\/\/doi.org\/10.1007\/s11356-022-19158-2","journal-title":"Environ Sci Pollut Res"},{"key":"1963_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4839230","volume":"2018","author":"C Pelaia","year":"2018","unstructured":"Pelaia C, Calabrese C, Vatrella A et al (2018) Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int 2018:1\u20139. https:\/\/doi.org\/10.1155\/2018\/4839230","journal-title":"Biomed Res Int"},{"key":"1963_CR83","doi-asserted-by":"publisher","DOI":"10.5530\/ijper.55.2.72","author":"K Prabahar","year":"2021","unstructured":"Prabahar K, Alanazi Z, Qushawy M (2021) Targeted drug delivery system\u202f: advantages, carriers and strategies. Indian J Pharm Educ Res. https:\/\/doi.org\/10.5530\/ijper.55.2.72","journal-title":"Indian J Pharm Educ Res"},{"key":"1963_CR84","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.arbr.2014.06.005","volume":"50","author":"S Quirce","year":"2014","unstructured":"Quirce S, Bobolea I, Dom\u00ednguez-Ortega J, Barranco P (2014) Future biologic therapies in asthma. Archivos De Bronconeumolog\u00eda (English Edition) 50:355\u2013361. https:\/\/doi.org\/10.1016\/j.arbr.2014.06.005","journal-title":"Archivos De Bronconeumolog\u00eda (English Edition)"},{"key":"1963_CR85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13223-017-0225-6","volume":"14","author":"J Quirt","year":"2018","unstructured":"Quirt J, Gagnon R, Ellis AK, Kim HL (2018) CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens. Allergy Asthma Clin Immunol 14:12\u201315. https:\/\/doi.org\/10.1186\/s13223-017-0225-6","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1963_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2023.100129","volume":"11","author":"MA Rajizadeh","year":"2023","unstructured":"Rajizadeh MA, Nematollahi MH, Jafari E et al (2023) Niosome nanocarrier enhances the ameliorating effects of myrtenol in the lungs of rats with experimental asthma. Open Nano 11:100129. https:\/\/doi.org\/10.1016\/j.onano.2023.100129","journal-title":"Open Nano"},{"key":"1963_CR87","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.omtn.2019.12.033","volume":"19","author":"SC Ramelli","year":"2020","unstructured":"Ramelli SC, Comer BS, McLendon JM et al (2020) Nanoparticle delivery of anti-inflammatory LNA oligonucleotides prevents airway inflammation in a HDM model of asthma. Mol Ther Nucleic Acids 19:1000\u20131014. https:\/\/doi.org\/10.1016\/j.omtn.2019.12.033","journal-title":"Mol Ther Nucleic Acids"},{"key":"1963_CR88","doi-asserted-by":"publisher","DOI":"10.2174\/0126667312289623240327073342","author":"BR Rane","year":"2024","unstructured":"Rane BR, Waghchaure PS, Amkar AJ, Jain AR (2024) Development and optimization of polymeric nanoparticles and their in vitro deposition studies using modified TSI. Curr Appl Mater. https:\/\/doi.org\/10.2174\/0126667312289623240327073342","journal-title":"Curr Appl Mater"},{"key":"1963_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wnan.1752","volume":"14","author":"PA Rawding","year":"2022","unstructured":"Rawding PA, Bu J, Wang J et al (2022) Dendrimers for cancer immunotherapy: avidity-based drug delivery vehicles for effective anti-tumor immune response. Wiley Interdiscip Rev Nanomed Nanobiotechnol 14:1\u201333. https:\/\/doi.org\/10.1002\/wnan.1752","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"1963_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107288","volume":"91","author":"J Ren","year":"2021","unstructured":"Ren J, Liu Y, Yao Y et al (2021) Intranasal delivery of MSC-derived exosomes attenuates allergic asthma via expanding IL-10 producing lung interstitial macrophages in mice. Int Immunopharmacol 91:107288. https:\/\/doi.org\/10.1016\/j.intimp.2020.107288","journal-title":"Int Immunopharmacol"},{"key":"1963_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/J.RMED.2023.107414","volume":"218","author":"L Rogers","year":"2023","unstructured":"Rogers L, Jesenak M, Bjermer L et al (2023a) Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient. Respir Med 218:107414. https:\/\/doi.org\/10.1016\/J.RMED.2023.107414","journal-title":"Respir Med"},{"key":"1963_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101677","author":"HA Saafan","year":"2021","unstructured":"Saafan HA, Ibrahim KM, Thabet Y et al (2021) Intratracheal administration of chloroquine-loaded niosomes minimize systemic drug exposure. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13101677","journal-title":"Pharmaceutics"},{"key":"1963_CR93","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2147\/copd.2006.1.4.425","volume":"1","author":"AM Sadowska","year":"2006","unstructured":"Sadowska AM, Verbraecken J, Darquennes K, Backer WD (2006) Role of N-acetylcysteine in the management of COPD. Int J COPD 1:425\u2013434. https:\/\/doi.org\/10.2147\/copd.2006.1.4.425","journal-title":"Int J COPD"},{"key":"1963_CR94","doi-asserted-by":"crossref","unstructured":"Santos A, Veiga F, Figueiras A (2020) Dendrimers as pharmaceutical excipients: synthesis, properties, toxicity and biomedical applications","DOI":"10.3390\/ma13010065"},{"key":"1963_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216042","volume":"24","author":"IA Savin","year":"2023","unstructured":"Savin IA, Zenkova MA, Sen\u2019kova AV (2023) Bronchial asthma, airway remodeling and lung fibrosis as successive steps of one process. Int J Mol Sci 24:16042. https:\/\/doi.org\/10.3390\/ijms242216042","journal-title":"Int J Mol Sci"},{"key":"1963_CR96","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2025.2529528","author":"N Sharma","year":"2025","unstructured":"Sharma N, Khatoon N, Raza MA et al (2025) A pioneer review on lactoferrin as versatile macromolecular ligand for targeting cancer: recent advances. J Drug Target. https:\/\/doi.org\/10.1080\/1061186X.2025.2529528","journal-title":"J Drug Target"},{"key":"1963_CR97","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1465-9921-11-26","volume":"11","author":"D Singh","year":"2010","unstructured":"Singh D, Petavy F, Macdonald AJ et al (2010) The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 11:26. https:\/\/doi.org\/10.1186\/1465-9921-11-26","journal-title":"Respir Res"},{"key":"1963_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2016.06.011","volume":"40","author":"D Singh","year":"2016","unstructured":"Singh D, Leaker B, Boyce M et al (2016) A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. Pulm Pharmacol Ther 40:1\u20136. https:\/\/doi.org\/10.1016\/j.pupt.2016.06.011","journal-title":"Pulm Pharmacol Ther"},{"key":"1963_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2022.100134","volume":"15","author":"A Sultana","year":"2022","unstructured":"Sultana A, Zare M, Thomas V et al (2022) Nano-based drug delivery systems: conventional drug delivery routes, recent developments and future prospects. Med Drug Discov 15:100134. https:\/\/doi.org\/10.1016\/j.medidd.2022.100134","journal-title":"Med Drug Discov"},{"key":"1963_CR100","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.4254\/wjh.v7.i22.2369","volume":"7","author":"A Tabll","year":"2015","unstructured":"Tabll A, Abbas AT, El-Kafrawy S, Wahid A (2015) Monoclonal antibodies: principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World J Hepatol 7:2369\u20132383. https:\/\/doi.org\/10.4254\/wjh.v7.i22.2369","journal-title":"World J Hepatol"},{"key":"1963_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.03.031","author":"K Tahara","year":"2016","unstructured":"Tahara K, Tomida H, Ito Y et al (2016) Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects. Int J Pharm. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.03.031","journal-title":"Int J Pharm"},{"key":"1963_CR102","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0954-6111(12)70005-7","volume":"106","author":"M Tamm","year":"2012","unstructured":"Tamm M, Richards DH, Begh\u00e9 B, Fabbri L (2012) Inhaled corticosteroid and long-acting \u03b22-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med 106:S9\u2013S19. https:\/\/doi.org\/10.1016\/S0954-6111(12)70005-7","journal-title":"Respir Med"},{"key":"1963_CR103","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2147\/JMDH.S313968","volume":"14","author":"A Tewabe","year":"2021","unstructured":"Tewabe A, Abate A, Tamrie M et al (2021) Targeted drug delivery\u2014from magic bullet to nanomedicine: principles, challenges, and future perspectives. J Multidiscip Healthc 14:1711\u20131724. https:\/\/doi.org\/10.2147\/JMDH.S313968","journal-title":"J Multidiscip Healthc"},{"key":"1963_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm11090860","volume":"11","author":"TC Theoharides","year":"2021","unstructured":"Theoharides TC (2021) Ways to address perinatal mast cell activation and focal brain inflammation, including response to SARS-CoV-2, in autism spectrum disorder. J Pers Med 11:1\u201324. https:\/\/doi.org\/10.3390\/jpm11090860","journal-title":"J Pers Med"},{"key":"1963_CR105","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jconrel.2023.11.034","volume":"365","author":"W Tu","year":"2024","unstructured":"Tu W, Hu X, Wan R et al (2024) Effective delivery of miR-511-3p with mannose-decorated exosomes with RNA nanoparticles confers protection against asthma. J Control Release 365:602\u2013616. https:\/\/doi.org\/10.1016\/j.jconrel.2023.11.034","journal-title":"J Control Release"},{"key":"1963_CR106","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.jaip.2022.03.027","volume":"10","author":"I V\u00e4h\u00e4talo","year":"2022","unstructured":"V\u00e4h\u00e4talo I, Lehtim\u00e4ki L, Tuomisto LE et al (2022) Long-term use of short-acting \u03b22-agonists in patients with adult-onset asthma. J Allergy Clin Immunol Pract 10:2074-2083.e7. https:\/\/doi.org\/10.1016\/j.jaip.2022.03.027","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1963_CR107","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.04.62","author":"L Wang","year":"2019","unstructured":"Wang L, Feng M, Li Q et al (2019) Advances in nanotechnology and asthma. Ann Transl Med. https:\/\/doi.org\/10.21037\/atm.2019.04.62","journal-title":"Ann Transl Med"},{"key":"1963_CR108","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1016\/j.sjbs.2021.04.009","volume":"28","author":"D Wang","year":"2021","unstructured":"Wang D, Mehrabi E, Shamsadin S (2021) Saudi Journal of Biological Sciences Study effect of Baicalein encapsulated\/loaded Chitosan-nanoparticle on allergic Asthma pathology in mouse model. Saudi J Biol Sci 28:4311\u20134317. https:\/\/doi.org\/10.1016\/j.sjbs.2021.04.009","journal-title":"Saudi J Biol Sci"},{"key":"1963_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13036-022-00298-5","volume":"16","author":"J Wang","year":"2022","unstructured":"Wang J, Li B, Qiu L et al (2022) Dendrimer-based drug delivery systems: history, challenges, and latest developments. J Biol Eng 16:1\u201312. https:\/\/doi.org\/10.1186\/s13036-022-00298-5","journal-title":"J Biol Eng"},{"key":"1963_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105409","volume":"117","author":"K W\u00f3jcik-Pszczo\u0142a","year":"2021","unstructured":"W\u00f3jcik-Pszczo\u0142a K, Jankowska A, \u015alusarczyk M et al (2021) Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. Bioorg Chem 117:105409. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105409","journal-title":"Bioorg Chem"},{"key":"1963_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110264","volume":"119","author":"K W\u00f3jcik-Pszczo\u0142a","year":"2023","unstructured":"W\u00f3jcik-Pszczo\u0142a K, Pociecha K, Ch\u0142o\u0144-Rzepa G et al (2023) Inhaled pan-phosphodiesterase inhibitors ameliorate ovalbumin-induced airway inflammation and remodeling in murine model of allergic asthma. Int Immunopharmacol 119:110264. https:\/\/doi.org\/10.1016\/j.intimp.2023.110264","journal-title":"Int Immunopharmacol"},{"key":"1963_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109180","volume":"112","author":"J Won","year":"2022","unstructured":"Won J, Jo A, Hee C et al (2022) International Immunopharmacology Inhaled delivery of recombinant interferon-lambda restores allergic inflammation after development of asthma by controlling Th2- and Th17-cell-mediated immune responses. Int Immunopharmacol 112:109180","journal-title":"Int Immunopharmacol"},{"key":"1963_CR113","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jconrel.2016.03.029","volume":"229","author":"Y Xie","year":"2016","unstructured":"Xie Y, Kim NH, Nadithe V et al (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120\u2013129. https:\/\/doi.org\/10.1016\/j.jconrel.2016.03.029","journal-title":"J Control Release"},{"key":"1963_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s41030-017-0043-5","volume":"3","author":"Q Ye","year":"2017","unstructured":"Ye Q, He X-O, D\u2019Urzo A (2017) A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther 3:1\u201318. https:\/\/doi.org\/10.1007\/s41030-017-0043-5","journal-title":"Pulm Ther"},{"key":"1963_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/J.NANTOD.2023.101942","volume":"52","author":"L Yue","year":"2023","unstructured":"Yue L, Zhang X, Zhao C et al (2023) Inhaled drug delivery: Past, present, and future. Nano Today 52:101942. https:\/\/doi.org\/10.1016\/J.NANTOD.2023.101942","journal-title":"Nano Today"},{"key":"1963_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.992731","author":"MS Zaazouee","year":"2022","unstructured":"Zaazouee MS, Alwarraqi AG, Mohammed YA et al (2022) Dupilumab efficacy and safety in patients with moderate to severe asthma: a systematic review and meta-analysis. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.992731","journal-title":"Front Pharmacol"},{"key":"1963_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126658","volume":"29","author":"M Zak","year":"2019","unstructured":"Zak M, Dengler HS, Rajapaksa NS (2019) Inhaled Janus kinase (JAK) inhibitors for the treatment of asthma. Bioorg Med Chem Lett 29:126658. https:\/\/doi.org\/10.1016\/j.bmcl.2019.126658","journal-title":"Bioorg Med Chem Lett"},{"key":"1963_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115144","volume":"203","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lu H, Xie L et al (2023) Inhaled RNA drugs to treat lung diseases: disease-related cells and nano\u2013bio interactions. Adv Drug Deliv Rev 203:115144. https:\/\/doi.org\/10.1016\/j.addr.2023.115144","journal-title":"Adv Drug Deliv Rev"},{"key":"1963_CR119","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.apsb.2018.01.007","volume":"8","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Quan G, Wu Q et al (2018) Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B 8:165\u2013177. https:\/\/doi.org\/10.1016\/j.apsb.2018.01.007","journal-title":"Acta Pharm Sin B"},{"key":"1963_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom9120790","volume":"9","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Liu C, Pang Z (2019) Dendrimer-based drug delivery systems for brain targeting. Biomolecules 9:1\u201329. https:\/\/doi.org\/10.3390\/biom9120790","journal-title":"Biomolecules"},{"key":"1963_CR121","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","volume":"197","author":"H Zuo","year":"2019","unstructured":"Zuo H, Cattani-Cavalieri I, Musheshe N et al (2019) Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther 197:225\u2013242. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.02.002","journal-title":"Pharmacol Ther"},{"key":"1963_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214427","author":"X Zuo","year":"2022","unstructured":"Zuo X, Guo X, Gu Y et al (2022) Recent advances in nanomaterials for asthma treatment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232214427","journal-title":"Int J Mol Sci"},{"key":"1963_CR123","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/IJN.S441345","volume":"19","author":"X Zuo","year":"2024","unstructured":"Zuo X, Gu Y, Guo X et al (2024) Preparation of budesonide-loaded liposomal nanoparticles for pulmonary delivery and their therapeutic effect in OVA-induced asthma in mice. Int J Nanomedicine 19:673\u2013688. https:\/\/doi.org\/10.2147\/IJN.S441345","journal-title":"Int J Nanomedicine"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01963-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01963-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01963-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:05:28Z","timestamp":1761332728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01963-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":123,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01963-z","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}